apposters.com
Tacalyx
Edit

Tacalyx

https://www.tacalyx.com/
Last activity: 30.04.2026
Active
Categories: AntibodiesBiotechDrugDiscoveryImmunotherapyOncology
Company developing therapeutics targeting cancer-specific carbohydrate antigens on the surface of metastatic malignant tumors
Website visits
8.9K /mo.
Mentions
9
Location: Germany
Employees: 11-50
Total raised: $20.82M
Founded date: 2019

Investors 5

Funding Rounds 2

DateSeriesAmountInvestors
30.04.2026-$12.88MCreathor V...
25.09.2019Seed$7.94M-

Mentions in press and media 9

DateTitleDescription
30.04.2026Tacalyx Raises €11 Million To Advance Lead Cancer Therapy Toward The ClinicTacalyx, a biotech company focused on the discovery and development of cancer therapies directed at Tumor Associated Carbohydrate Antigens, has secured €11 million in a first closing of its seed extension round to advance its lead clinical ...
20.06.2023Biotech Breakthroughs: Unraveling Germany’s 15 Emerging Biotechnology StartupsEmergence Therapeutics led by Jack Elands, is a promising biopharmaceutical company dedicated to advancing novel ADC immunotherapies to address cancers with high unmet needs. Table of Contents show 1 FaCellitate – Supporting Drug Discover...
25.09.2019Tacalyx Secures €7M in Seed FundingTacalyx, a Berlin, Germany-based biotech company focused on the discovery and development of novel anti-TACA (Tumor Associated Carbohydrate Antigens) cancer therapies, secured €7m in seed funding. The round was co-led by Boehringer Ingelhei...
25.09.2019Top tech startup news for today, Wednesday, September 25, 2019Good morning! Below are some of the top tech startup news for today, Wednesday, September 25, 2019. Alibaba unveiled Hanguang 800, its first chip to power artificial intelligence (AI) processes. Alibaba is following Huawei’s footsteps with...
25.09.2019Berlin-based biotech startup Tacalyx raises €7 million to create anti-TACA antibodies for cancer treatmentBerlin-based biotech startup Tacalyx, which develops novel anti-TACA (Tumor Associated Carbohydrate Antigens) cancer therapies, has just secured €7 million in a seed funding round. The round comes from a syndicate of European life science a...
25.09.2019German Biotech startup Tacalyx secures $7.7 million in seed funding to create anti-TACA antibodies for cancer treatmentTacalyx, a biotech oncology startup company focused on the discovery and development of Tumor Associated Carbohydrate Antigen (TACA) antibodies to treat cancer, has raised $7.7 million (€7 million) in seed funding to advance its discovery p...
-Tacalyx Raises €7 Million in Seed Funding to Generate First in Class Anti-TACA Antibodies for Cancer TreatmentTacalyx, a biotech company focused on the discovery and development of novel anti-TACA (Tumor Associated Carbohydrate Antigens) cancer therapies, today announced that it has successfully secured €7 million in seed funding. The funding round...
-Tacalyx“Home – Tacalyx GmbH ”
-Tacalyx Raises €7 Million to Generate Anti-TACA Antibodies for Cancer TreatmentTacalyx, a biotech company focused on the discovery and development of novel anti-TACA (Tumor Associated Carbohydrate Antigens) cancer therapies, today announced that it has successfully secured €7 million in seed funding. The funding round...

Reviews 0

Sign up to leave a review

Sign up Log In